CNS-invasive aspergillosis following ibrutinib therapy
<p>Ibrutinib is Bruton's tyrosine kinase inhibitor that now become the standard of care for the treatment of CLL (chronic lymphocytic leukemia) and other lymphoid cancers. With its increasing usage, oncologists must become more aware of their potential side effect profile. Ibrutinib is ty...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Book |
| Published: |
International Journal of Immunotherapy and Cancer Research - Peertechz Publications,
2022-12-08.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|